Home Stocks ZYME Zymeworks Inc. Common Stock (NASDAQ: ZYME) Healthcare · Biotechnology
$26.04 +0.20 (+0.77%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. ZYME rose 0.77% in the Nov 18 session to $26.04, which is 17.2% below its 52-week high of $31.46. Short interest is 8.99% of float with a 0.41% borrow fee. 11 active firms cover the stock as of Nov 19, 2026; ten active firms with targets average $43.00 over 12 months, and the next earnings report is due Mar 4, 2027. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Higher multiples than peers P/S 55.4× vs peer median 13.9×
Momentum Neutral RSI (14) 42.7 (overbought above 70, oversold below 30)
Short interest 9.0% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $25.65 Nov 18, 2026 session
Previous close $25.84 Nov 17, 2026 close
Day range $24.88 – $26.24 Nov 18, 2026 session
52-week range $21.81 – $31.46 Through Nov 18, 2026
Volume 1.02M Nov 18, 2026 session
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $2.06B
P/E (TTM) 3.8
Forward P/E 31.3
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 1.31
Price history ZYME · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
How ZYME compares with its industry Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsThree-month return was -5%, higher than 84% of 559 peers.Peer median −31.7% · As of Nov 16, 2026 Points of cautionLatest-quarter year-over-year sales growth was -90.6%, with only 12% of 592 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Valuation Higher multiples than peers
Metric ZYME Peer median
Profitability Profitability metrics are lower than most peers.
Metric ZYME Peer median
Gross margin — 78.4%
Not ranked: only 247 of 592 peers report it
Operating margin — 0.0%
Not ranked: only 443 of 592 peers report it
Net margin 0.0% 0.0%
Higher than 19% of 583 peers
Return on equity −72.3% −67.8%
Higher than 48% of 554 peers
Growth Growth metrics are lower than most peers.
Metric ZYME Peer median
Quarterly sales growth, year over year −90.6% 0.0%
Higher than 12% of 592 peers
5-year sales growth rate 22.2% 11.0%
Not ranked: only 139 of 592 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric ZYME Peer median
Momentum Returns are higher than most peers.
Metric ZYME Peer median
1-year return +39.5% −29.8%
Higher than 82% of 522 peers
6-month return +5.9% −24.0%
Higher than 73% of 547 peers
3-month return −5.0% −31.7%
Higher than 84% of 559 peers
How to read this The dot marks where ZYME ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 12, 2026
Analyst consensus Buy
0 Strong Buy
11 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 11 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $32.00
Average $43.00
High $58.00
As of Nov 19, 2026 across 10 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −2.00 −1.00 0.00 1.00 2.00 3.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 $2.19 $2.28 —
Q2 2026 — −$0.62 —
Q1 2026 — −$0.59 —
Annual 2025 −$0.32 −$1.08 —
Q3 2025 −$0.32 −$0.26 —
Q2 2025 −$0.52 $0.03 —
Q1 2025 −$0.70 −$0.30 —
Annual 2024 −$0.09 −$1.62 —
Next: Mar 4, 2027, estimate $0.08
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Nov 10, 2022 Insider sell Josephson Neil Sell $20.0K Form 4 All smart-money activity →
News and press releases Year All 2026 Nov 16, 2026, 6:00 AM ET Nov 9, 2026, 4:05 PM ET Oct 24, 2026, 2:30 AM ET Oct 23, 2026, 6:00 AM ET Oct 19, 2026, 6:00 AM ET Oct 15, 2026, 6:00 AM ET Sep 28, 2026, 6:00 AM ET Sep 23, 2026, 4:01 PM ET Aug 25, 2026, 10:23 AM ET Aug 11, 2026, 6:00 AM ET All ZYME news → Company profile Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a
CEO Mr. Kenneth H. Galbraith C.A.
Headquarters Middletown, DE, United States
Employees 231
IPO date Apr 28, 2017
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Analyst consensus Buy
0 Strong Buy
11 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 11 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $32.00
Average $43.00
High $58.00
As of Nov 19, 2026 across 10 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −2.00 −1.00 0.00 1.00 2.00 3.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 $2.19 $2.28 —
Q2 2026 — −$0.62 —
Q1 2026 — −$0.59 —
Annual 2025 −$0.32 −$1.08 —
Q3 2025 −$0.32 −$0.26 —
Q2 2025 −$0.52 $0.03 —
Q1 2025 −$0.70 −$0.30 —
Annual 2024 −$0.09 −$1.62 —
Next: Mar 4, 2027, estimate $0.08
Company profile Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a
CEO Mr. Kenneth H. Galbraith C.A.
Headquarters Middletown, DE, United States
Employees 231
IPO date Apr 28, 2017
Sector Healthcare
Industry Biotechnology